Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bristol-Myers Plans Biologics Expansion

by Rick Mullin
April 22, 2013 | A version of this story appeared in Volume 91, Issue 16

[+]Enlarge
Credit: Bristol-Myers Squibb
A cell culture reactor at the Devens site.
A cell culture reactor at Bristol-Myers Squibbs’s Devens, Mass., plant.
Credit: Bristol-Myers Squibb
A cell culture reactor at the Devens site.

Bristol-Myers Squibb will expand its large-scale biologics manufacturing facility in Devens, Mass. The $250 million project will add biologics development and clinical trial production capabilities to the four-year-old site with separate new buildings for each operation. The firm also plans to add 350 employees. “This project represents a significant expansion in both the size and mission of Devens,” says Peter Moesta, head of biologics manufacturing and process development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.